A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
2 other identifiers
interventional
N/A
1 country
1
Brief Summary
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2002
CompletedFirst Posted
Study publicly available on registry
April 30, 2002
CompletedJuly 19, 2006
July 1, 2006
April 29, 2002
July 18, 2006
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- confirmed diagnosis of breast cancer
- measurable disease
- received prior anthracycline and taxane
- life expectancy \> 3 months
- acceptable lab results
You may not qualify if:
- \>3 prior regimens
- prior treatment with protocol drugs
- prior (pelvic) radiation
- active CNS metastasis
- inability to take oral vitamins
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unknown Facility
Rochester, Minnesota, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 29, 2002
First Posted
April 30, 2002
Last Updated
July 19, 2006
Record last verified: 2006-07